1
|
Rugge M, Fassan M and Graham DY:
Epidemiology of gastric cancer. Gastric Cancer. 1–34.
2015.PubMed/NCBI
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Trinchieri G: Cancer and inflammation: An
old intuition with rapidly evolving new concepts. Annu Rev Immunol.
30:677–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chung HW and Lim JB: Role of the tumor
microenvironment in the pathogenesis of gastric carcinoma. World J
Gastroenterol. 20:1667–1680. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Mroczko B, Łukaszewicz-Zajac M,
Guzińska-Ustymowicz K, Gryko M, Czyzewska J, Kemona A, Kedra B and
Szmitkowski M: Expression of matrix metalloproteinase-9 in the
neoplastic and interstitial inflammatory infiltrate cells in
gastric cancer. Folia Histochem Cytobiol. 47:491–496.
2009.PubMed/NCBI
|
6
|
Dalgleishl AG and O'Byrne K: Inflammation
and cancer. Nature. 420:1–3849. 2014.
|
7
|
Rivera LB, Meyronet D, Hervieu V,
Frederick MJ, Bergsland E and Bergers G: Intratumoral myeloid cells
regulate responsiveness and resistance to antiangiogenic therapy.
Cell Rep. 11:577–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Theoharides TC, Alysandratos K-D,
Angelidou A, Delivanis D-A, Sismanopoulos N, Zhang B, Asadi S,
Vasiadi M, Weng Z, Miniati A and Kalogeromitros D: Mast cells and
inflammation. Biochim Biophys Acta. 1822:21–33. 2013. View Article : Google Scholar
|
9
|
Raica M, Cimpean AM, Ceausu R, Ribatti D
and Gaje P: Interplay between mast cells and lymphatic vessels in
different molecular types of breast cancer. Anticancer Res.
33:957–963. 2013.PubMed/NCBI
|
10
|
Rabenhorst A, Schlaak M, Heukamp LC,
Förster A, Theurich S, von Bergwelt-Baildon M, Büttner R, Kurschat
P, Mauch C, Roers A and Hartmann K: Mast cells play a
protumorigenic role in primary cutaneous lymphoma. Blood.
120:2042–2054. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Griffith JW, Sokol CL and Luster AD:
Chemokines and chemokine receptors: Positioning cells for host
defense and immunity. Annu Rev Immunol. 32:659–702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Deshmane SL, Kremlev S, Amini S and Sawaya
BE: Monocyte chemoattractant protein-1 (MCP-1): An overview. J
Interferon Cytokine Res. 29:313–326. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tsaur I, Noack A, Makarevic J, Oppermann
E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter
M, et al: CCL2 chemokine as a potential biomarker for prostate
cancer: A pilot study. Cancer Res Treat. 47:306–312. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Rokavec M, Wu W and Luo JL: IL6-mediated
suppression of miR-200c directs constitutive activation of
inflammatory signaling circuit driving transformation and
tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu J, Liu X and Wang Y: Predictive value
of preoperative serum CCL2, CCL18 and VEGF for the patients with
gastric cancer. BMC Clin Pathol. 13:152013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ray P, Krishnamoorthy N and Ray A:
Emerging functions of c-kit and its ligand stem cell factor in
dendritic cells: Regulators of T cell differentiation. Cell Cycle.
7:2826–2832. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Amagai Y, Tanaka A, Matsuda A, Jung K,
Ohmori K and Matsuda H: Stem cell factor contributes to
tumorigenesis of mast cells via an autocrine/paracrine mechanism. J
Leukoc Biol. 93:245–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Suphanantachat S, Iwata T, Ishihara J,
Yamato M, Okano T and Izumi Y: A role for c-Kit in the maintenance
of undifferentiated human mesenchymal stromal cells. Biomaterials.
35:3618–3626. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ashman LK and Griffith R: Therapeutic
targeting of c-KIT in cancer. Expert Opin Investig Drugs.
22:103–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Huscher CG, Mingoli A, Sgarzini G,
Sansonetti A, Di Paola M, Recher A and Ponzano C: Laparoscopic
versus open subtotal gastrectomy for distal gastric cancer:
Five-year results of a randomized prospective trial. Ann Surg.
241:232–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H
and Zou X: Report of cancer incidence and mortality in China, 2010.
Ann Transl Med. 2:612014.PubMed/NCBI
|
22
|
Ferro A, Peleteiro B, Malvezzi M, Bosetti
C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N:
Worldwide trends in gastric cancer mortality (1980–2011), with
predictions to 2015, and incidence by subtype. Eur J Cancer.
50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ribatti D, Guidolin D, Marzullo A, Nico B,
Annese T, Benagiano V and Crivellato E: Mast cells and angiogenesis
in gastric carcinoma. Int J Exp Pathol. 91:350–356. 2010.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Rabenhorst A, Schlaak M, Heukamp LC,
Förster A, Theurich S, von Bergwelt-Baildon M, Büttner R, Kurschat
P, Mauch C, Roers A and Hartmann K: Mast cells play a
protumorigenic role in primary cutaneous lymphoma. Blood.
120:2042–2054. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y and
Zhao LJ: Prognostic significance of cell infiltrations of
immunosurveillance in colorectal cancer. World J Gastroenterol.
11:1210–1214. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Rajput AB, Turbin DA, Cheang MC, Voduc DK,
Leung S, Gelmon KA, Gilks CB and Huntsman DG: Stromal mast cells in
invasive breast cancer are a marker of favourable prognosis: A
study of 4,444 cases. Breast Cancer Res Treat. 107:249–257. 2008.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Amini RM, Aaltonen K, Nevanlinna H,
Carvalho R, Salonen L, Heikkilä P and Blomqvist C: Mast cells and
eosinophils in invasive breast carcinoma. BMC Cancer. 7:1652007.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Huang Y, Chen H, Wang J, Bunjhoo H, Xiong
W, Xu Y and Zhao J: Relationship between CCR2-V64I polymorphism and
cancer risk: A meta-analysis. Gene. 524:54–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Tao LL, Shi SJ, Chen LB and Huang GC:
Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer
and its relationship with tumor hypoxia. World J Gastroenterol.
20:4421–4427. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast tumor metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Low-Marchelli JM, Ardi VC, Vizcarra EA,
van Rooijen N, Quigley JP and Yang J: Twist1 induces CCL2 and
recruits macrophages to promote angiogenesis. Cancer Res.
73:662–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhang J, Patel L and Pienta KJ: CC
chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis
and metastasis. Cytokine Growth Factor Rev. 21:41–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Li X, Xu Q, Wu Y, Li J, Tang D, Han L and
Fan Q: A CCL2/ROS autoregulation loop is critical for cancer
associated fibroblasts-enhanced tumor growth of oral squamous cell
carcinoma. Carcinogenesis. 35:1362–1370. 2014. View Article : Google Scholar : PubMed/NCBI
|